Quest Diagnostics Inc vs Western Union Co — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Western Union Co trades at $7.85 (market cap $2.46B). The key difference: Quest Diagnostics Inc is far larger — about 9.3× Western Union Co's market cap, and Western Union Co pays the higher dividend (11.93%). Which is the better fit depends on your goals.
| DGX | WU | |
|---|---|---|
Market Cap | $22.80B | $2.46B |
Sector | Health | Technology |
52-Week High | $216.02 | $10.28 |
52-Week Low | $166.42 | $7.04 |
Enterprise Value | $28.82B | $2.16B |
Dividend Yield | 1.67% | 11.93% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Western Union (WU) trades at $7.87, up 0.38% with a bullish technical signal. The stock shows attractive valuation with P/E of 5.79 and P/S of 0.63, supported by strong profitability metrics including 47.66% ROE. Recent earnings show mixed performance with Q1 2026 miss but Q3 and Q4 2025 beats. The company maintains strategic partnerships with Total Wireless and digital expansion initiatives, though revenue has declined from $4.5B in 2022 to $4.05B in 2025.
WU presents a value opportunity with deep valuation discounts but faces revenue headwinds and competitive pressures. The 11.5% dividend yield provides income support, though high debt levels and declining net income margins warrant caution. Analyst consensus remains mixed with 58% hold ratings, reflecting balanced risk-reward amid digital transformation efforts.
Trailing returns across standard periods
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →